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PyrophosphateEcto-nucleotide pyrophosphatase/phosphodiesterases (NPPs) hydrolyse nucleotide triphosphates to the
corresponding nucleotide monophosphates and the mineralisation inhibitor, pyrophosphate (PPi). This study
examined the role of NPP1 in osteocytes, osteoclasts and cortical bone, using a mouse model lacking NPP1
(Enpp1−/−). We used microcomputed tomography (μCT) to investigate how NPP1 deletion affects cortical
bone structure; excised humerus bones from 8, 15 and 22-week old mice were scanned at 0.9 μm. Although no
changes were evident in the cortical bone of 8-week old Enpp1−/−mice, significant differences were observed
in older animals. Cortical bone volume was decreased 28% in 22-week Enpp1−/−mice, whilst cortical porosity
was reduced 30% and 60% at 15 and 22-weeks, respectively. This was accompanied by up to a 15% decrease in
closed pore diameter and a 55% reduction in the number of pores. Cortical thickness was reduced up to 35% in
15 and 22-week Enpp1−/− animals and the endosteal diameter was increased up to 23%. Thus, the cortical
bone from Enpp1−/−micewas thinner and less porous, with a larger marrow space. Scanning electronmicrosco-
py (SEM) revealed a decrease in the size and number of blood vessel channels in the cortical bone aswell as a 40%
reduction in the mean plan area of osteocyte lacunae. We noted that the number of viable osteocytes isolated
from the long bones of Enpp1−/− mice was decreased ≤50%. In contrast, osteoclast formation and resorptive
activity were unaffected by NPP1 deletion. μCT and histological analysis of Enpp1−/−mice also revealed calcifica-
tion of the joints and vertebrae as well as soft tissues including the whisker follicles, ear pinna and trachea. This
calcification worsened as the animals aged. Together, these data highlight the key role of NPP1 in regulating
calcification of both soft and skeletal tissues.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
The ability of pyrophosphate (PPi) to inhibit mineralisation was first
identified in the 1960s by Fleisch and colleagues [1]. It is now accepted
that the ratio of PPi to phosphate (Pi) within the bonemicroenvironment
is a fundamental regulator of the level of mineralisation [2,3]. PPi can be
generated fromnucleotide triphosphates (such as ATP or UTP) by the ac-
tions of ecto-nucleotidase pyrophosphatase/phosphodiesterases (NPPs).
These transmembrane proteins display widespread expression and are
highly conserved between species. Osteoblasts express at least 3 mem-
bers of the NPP family (NPP1, 2, 3) [4–6], and of these, NPP1 (previously
called plasma cell membrane glycoprotein 1 or PC-1), is thought to betive Biomedical Science, Royal
. This is an open access article underthe most important NPP in PPi generation. Tissue-nonspecific alkaline
phosphatase (TNAP) is the key enzyme involved in PPi breakdown [4].
Previous work has shown that the opposing actions of NPP1 and TNAP
are critical in determining the extracellular Pi/PPi ratio and, thus, the
level of skeletal mineralisation [5]. Furthermore, the inhibitory actions
of ATP and UTP on bone mineralisation appear to be partly mediated
via the actions of NPP1 [6–8].
NPP1 expression has now been demonstrated in a wide range of tis-
sues and cell types including the heart, kidney, vascular smooth muscle
cells and chondrocytes [9–12]. In addition to its role in regulating
mineralisation, NPP1 is also thought to be involved in glucose homeo-
stasis and insulin signalling [13–15]. Mutations in the gene encoding
NPP1 (Enpp1) have been associatedwith a rare autosomal recessive dis-
ease generalised arterial calcification of infancy (GACI) [16]. Sufferers of
this condition usually die in infancy because of substantial vascular
calcification.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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has been highlighted by two different mouse models; the naturally oc-
curring NPP1 ‘knockout’ termed the tip-toe walking (ttw/ttw) mouse
and the genetically altered NPP1 knockout (Enpp1−/−). The ttw/ttw
model displays ossification of the spinal ligaments, peripheral joint
hyperstosis and calcification of articular cartilage [17]. The pheno-
type of ttw/ttwmice also has similarities to the human disease ‘Ossi-
fication of the posterior longitudinal ligament of the spine’ (OPLL). The
Enpp1−/− model displays a number of defects related to reduced PPi
production, including calcification of the aorta, kidney, spine, joints
and cartilage [4,18–21]. Suprisingly, given the reduction in extracellular
PPi levels, Enpp1−/−mice display reduced trabecular and cortical bone
in the long bones and decreased bone strength [20]. These animals
also have increased FGF-23 levels [20] and decreased osteopontin levels
[19]. Earlier work also showed an increased number of osteoclasts on
the ex vivo bone surfaces of Enpp1−/− mice [20]. This was associated
with an increase in the blood serum concentration of the bone resorp-
tion marker, C-terminal telopeptides of type I collagen (CTx), and sug-
gests increased osteoclast activity in Enpp1−/− animals [20].
Osteocytes, the most abundant cell type in bone [22], reside within
lacunae surrounded bymineralisedmatrix. Extensive dendritic process-
es extend through canaliculi to form a highly connected communication
network between osteocytes and the other cells on the bone surface.
Soluble factors released by osteocytes regulate osteoblast and osteoclast
function thereby providing a mechanism to control bone remodelling
[23,24]. Osteocytes also play a role in phosphate metabolism, calcium
availability and are the primary mechanosensory cell within bone [24]
. The viability of osteocytes plays a significant role in maintaining bone
homeostasis as cell death has been associated with pathological condi-
tions such as osteoporosis and osteoarthritis [24,25].
Mature osteoblasts express high levels of NPP1 [26] and, conse-
quently, most studies to date have focused on the role of this enzyme
in bone mineralisation and/or osteoblast differentiation [20,27,28].
The aim of this investigation was to determine whether the actions of
NPP1 affect osteocyte function and cortical bone structure. The ability
of NPP1 to influence osteoclast formation and bone resorption was
also examined.
Methods
Reagents
All tissue culture and molecular biology reagents were purchased
from Life Technologies (Paisley, UK) unless stated otherwise. Chemical
reagents were purchased from Sigma Aldrich (Poole, Dorset, UK).
Enpp1−/−mice
The generation and characterisation of Enpp1−/−mice, which are on
a 129Sv/TerJ genetic background, have previously been described [29].
All animal experiments were approved by UCL's animal users commit-
tee and animals were maintained in accordance with UK Home Office
guidelines for the care and use of laboratory animals.
Microcomputed tomographic (μCT) analysis of Enpp1−/−mice
The humerus, head, knees, spine, trachea and paws were isolated
from 8, 15 and 22-week old Enpp1−/− and wild-type (Enpp1+/+) mice
and fixed in 10% neutral buffered formalin for 24 h. Samples were
then washed in phosphate buffered saline and stored in 70% ethanol
until scanning. All scans were performed using a Skyscan 1172 μCT
scanner (Bruker, Kontich, Belgium). The humerus bones were scanned
at 50 kV and 20 μA, using a 0.25 mm aluminium filter and a resolution
of 0.9 μm. All other tissues were scanned using an image pixel size of
between5–10 μmand a 0.5mmaluminiumfilter. To analyse the cortical
bone of the humerus, a 0.25mm region of interest was selected 0.5 mmbelow the deltoid tuberosity. The images were reconstructed using
the Skyscan Nrecon software and analysed using the Skyscan CTan
program.
Histology
Histological analysis was performed on the trachea, ears and
whisker follicles of Enpp1+/+ and Enpp1−/− mice. Tissues were fixed
in 10% neutral buffered formalin and infiltrated with paraffin wax
using an automated tissue processor (Leica Microsystems, Wetzlar,
Germany). Samples were manually set within paraffin wax blocks
before being cut into 3 μm sections and mounted onto slides. Before
staining, the samples were de-paraffinised using xylene, then rehydrated
through a series of decreasing ethanol solutions and finally water. Slides
were stained for calcium using alizarin red (1% w/v), washed three
times in deionised water and counter-stained with fast green (1% w/v).
After staining, the samples were covered with a glass cover slip and
imaged using a Nanozoomer slide imaging system (Hamamatsu, Hama-
matsu City, Japan).
Scanning electron microscopy
The femurs were dissected from 15 and 22-week old Enpp1+/+ and
Enpp1−/− mice and cut along the longitudinal axis using a Buehler
Isomet saw (Düsseldorf, Germany). The bonemarrow, and any remain-
ing soft tissue, was digested away in a 6% Tergazyme solution, pH 8.0
(Alconox, White Plains, NY, USA), for three weeks. The bones were
dehydrated (50% ethanol, 2 h; 70% ethanol, 2 h; 100% ethanol, over-
night) before being left to air dry. Images from the 15 and 22-week
old animals were taken using a Zeiss EVO MA10 scanning electron
microscope (SEM) (Zeiss, Oberkochen, Germany) at Queen Mary,
University of London or a JEOL 7401 SEM (JEOL, Tokyo, Japan) at UCL,
respectively. Analysis of SEM images (Image J, NIH, USA) was used to
determine the number and size of blood vessel channels and osteocyte
lacunae. A 2.0 mm region of interest located 4 mm below the growth
plate on the endosteal surface of the cortical bone was selected for
image analysis.
Mouse osteocyte-like and osteoblast cell culture
Primary mouse osteocytes were obtained from the long bones of
15-week old Enpp1+/+ and Enpp1−/− using the methods described by
Stern and colleagues [30]. Following isolation, cells were seeded onto
collagen coated 6-well trays at a density of 2 × 105 cells per well in
αMEM. Half media changes were performed on every third day; the
cells were used for experimental procedures on day 7. The number of
cells present was counted manually using light microscopy.
Mouse osteoblasts were obtained from the calvaria of neonatal
Enpp1+/+ and Enpp1−/− mice by trypsin/collagenase digestion as
described previously [31]. Cells were cultured for up to 28 days
in αMEM supplemented with 50 μg/ml ascorbate and 2 mM β-
glycerophosphate.
Total RNA extraction and complimentary DNA strand synthesis
Osteoclasts were cultured on dentine discs for up to 10 days before
RNA was extracted using TRIzol® reagent according to the
manufacturer's instructions. RNA was extracted from osteoblasts
and osteocytes on day 21 and day 7 of culture, respectively. Before
first stand complementary DNA (cDNA) synthesis extracted RNA
was treated with RNase-free DNase I (35 U/ml) (Promega, South-
ampton, UK) for 30 min at 37 °C. The reaction was terminated by
heat inactivation at 65 °C for 10min. Total RNAwas quantified spectro-
photometrically by measuring absorbance at 260 nm. For each sam-
ple, 0.5 μg of DNase-treated total RNA was used as a template for first
strand cDNA synthesis in a 20 μl reaction also containing 0.5 μg oligo dT,
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hibitor, ImProm-II® 5× reaction buffer and 200U ImProm-II reverse tran-
scriptase. The reaction mix was annealed for 5 min at 25 °C, followed by
extension at 42 °C for 60 min and inactivation at 70 °C for 15 min.
cDNA was stored at−20 °C until amplification by RT-PCR or qRT-PCR.RT-PCR
Osteoclast and osteocyte-derived cDNA was amplified by PCR in
25 μl reactions containing ~0.5 μg cDNA, 0.2 mM dNTP, 1.5 mMMgCl2,
0.2 μM of both sense and anti-sense primer, 1 U Taq DNA polymerase
in thermophilic DNA polymerase 10× buffer. PCR was performed
according to the manufacturer's instructions for between 30–40 cycles
of amplification. Denaturation at 95 °C for 30 s, annealing for 30 s at a
primer specific temperature and extension at 72 °C for 45 s took place
within each cycle, followed by reaction termination at 72 °C for 5 min.
For analysis, PCR products were loaded on to 1% agarose gels containing
0.3 μg/ml ethidium bromide. Gels were run at ~80mA and the DNA po-
sition visualised by exposure to UV light. To account for differences in
original cell number and cDNAquality, osteoclast sampleswere normal-
ised against mRNA for GAPDH. All reactions were carried out in
triplicate using cDNAs derived from 3 different osteoclast/osteocyte
cultures. Primer sequences are shown in Table 1. The RT-PCR positive
control used samples from mouse brain.Quantitative real-time PCR (qRT-PCR)
Osteoblast and osteocyte cDNAs were amplified using specific
QuantiTect primers (β-actin, sclerostin) and QuantiTect SYBR® Green
(Qiagen Ltd, Crawley UK). qRT-PCR (Chromo4, Biorad Laboratories Ltd,
Hemel Hempstead, UK) was performed according to manufacturer's in-
structions with an initial activation step (94 °C for 15 min) followed by
40 cycles of denaturation (95 °C for 10 s) and detection (60 °C for 30 s).
Gene expression was investigated in osteocytes and mature, bone
forming osteoblasts. Data was analysed using the Pfaffl method [32]
and is shown as relative expression of sclerostin in Enpp1+/+ and
Enpp1−/− cells. All reactions were carried out in triplicate using RNAs
derived from 3 different osteoblast/osteocyte cultures.Measurement of serum sclerostin
Blood was collected from 8, 15 and 22-week old Enpp1−/− and
Enpp1+/+ mice by cardiac puncture immediately after termination.
Following clotting, samples were centrifuged at 500 g and the serum
was retained and frozen until analysis. Serum sclerostin was measured
using a commercially available ELISA kit (R&D systems, Abingdon,
UK), as per the manufacturer's instructions. It is unknown which of
the many forms of secreted sclerostin [33] are detected by this kit.Table 1 Primer sequences for RT-PCR.
Mus musculus gene Sense 5′–3′ Anti-sense 5′–3′
GAPDH CTCACTCAAGATTGTCAGCA GTCATCATACTTGGCAGGTT
Enpp1 ACAGCTTAATCTGACCACAG GATCCTGGTACAGACAGTTG
Enpp2 GTATGACCCTGTCTTTGATG GAAAGCCACTGAAGGATAGT
Enpp3 CTGCTGACTGTGGTTTTACT CTGTGGTAAAGGAGACAGTG
NTPdase1 CTTTGGCGCTTTGGATCTCG TCTGGTGGCACTGTTCGTAG
NTPdase2 CTGGAGGCAGTGACACAGAC TGGGTGGAGTAGCCCTTTGG
NTPdase3 GTGAGCATTGTGGTACTTGT TGACCACTCCTGTGTTATTC
ANK CAGTTTCCTGGTGGGATGTG TTGATGTGGGCTGAGGTG
GAPDH = glyceraldehyde-3-phosphate dehydrogenase, Enpp = ecto-nucleotide
pyrophosphatase/phosphodiesterase, NTPdase = ecto-nucleoside triphosphate
diphosphohydrolase, ANK = progressive ankylosis gene.Measurement of extracellular ATP
Prior to measurement of ATP levels, culture medium was removed,
cell layers were washed and cells were incubated with serum-free
DMEM (1 ml/well) for 1 h. Extracellular ATP release was measured
luminetrically using the luciferin–luciferase assay as previously reported
[34]. Cell number was determined using the CytoTox 96® non-
radioactive cytotoxicity assay (Promega, Southampton, UK).
Osteoclast formation assay
Osteoclasts were generated from the bone marrow of 8 or 15-week
old Enpp1+/+ or Enpp1−/− mice as previously reported [35]. Briefly,
cells were plated onto 5 mm diameter dentine discs (106 cells) in
αMEM supplemented with 100 nM PGE2, 200 ng/ml M-CSF and
3 ng/ml receptor activator of nuclear factor ΚB (RANKL; R&D Systems
Europe Ltd, Abingdon, UK). After 24 h, discs containing adherent osteo-
clast precursors were transferred to 6 well trays (4 discs/well in 4 ml
medium) for a further 6 days at 37 °C in 5% CO2/95% atmospheric air.
Culture medium was acidified to pH ~7.0 by the addition 10 meq/l H+
(as HCL) on day 7 to activate osteoclastic resorption of dentine
[35–38]. Culture medium pH, pCO2 and PO2 were monitored through-
out using a blood gas analyser (ABL 705, Radiometer, Copenhagen,
Denmark). Osteoclasts were fixed in 2% glutaraldehyde and stained to
demonstrate tartrate-resistant acid phosphatase (TRAP). Osteoclasts
were defined as TRAP-positive cells with 2 or more nuclei and/or clear
evidence of resorption pit formation. Osteoclast number and the plan
surface area of resorption pits were measured as described previously
[35].
Total cellular NPP activity measurement
The assay used to measure total cellular NPP activity was based on
the method originally described by Razzell and Khorana [39]. Briefly,
cells were lysed in a buffer containing 1% triton × 100 in a 0.2 M Tris
base with 1.6 mMMgCl2, pH 8.1. Following centrifugation at 500 g the
NPP activity of collected supernatants was measured using 5 mM p-
nitrophenyl-thymidine 5′-monophosphate as substrate. Total protein
concentration in cell l lysateswasmeasured using the Bradfordmethod.
Statistics
Statistical comparisonsweremade using a t-test or one-way analysis
of variance (ANOVA) and adjusted using the Bonferronimethod [40,41].
Calculations were performed using In Stat 3 (GraphPad, San Diego, CA).
All data are presented as means ± SEM for between 6–12 replicates.
Results are representative of experiments performed at least three
times, unless otherwise stated.
Results
Ectopic mineralisation in Enpp1−/−mice
Previous studies have reported aberrant mineral deposition in
Enpp1−/− mice [4,20,27]. Here, we used μCT imaging to visualise
this ectopic mineralisation at high resolution. Enpp1−/− mice
displayed mineralisation between the vertebrae (Fig. 1A) and of
the ligaments within the knee joint (Fig. 1B). Within the paws,
there was mineralisation of the joint capsules and the metatarsals
and phalanges were partially fused together (Fig. 1C).
Interestingly, we also observed mineral deposits in several collagen
rich soft tissues including the whisker follicles, trachea and ear pinna
of Enpp1−/−mice (Figs. 1D–H). The mineralisation of the whisker folli-
cles was sub-dermal, not visible to the naked eye, nor easily detectable
by touch. To ensure that themineralisation of the vibrissae observed by
μCTwas not an artefact of the scanning, histologywas performed on the
Fig. 1. μCT and histology show that Enpp1−/−mice have nonspecific tissuemineralisation. μCT imaging was used to visualise the spine (A), knee joints (B) and paws (C) of Enpp1+/+ and
Enpp1−/−mice. Dystrophicmineralisationwas seenbetween the vertebrae, within the knee joint, and surrounding the joints of the paw. (D) μCT scanning of the heads from Enpp1+/+ and
Enpp1−/−mice with all the soft tissue attached indicated that whisker follicles and ear pinna were mineralised. (E) Alizarin red staining of histological sections showed that the collagen
ring that sounds the whisker was mineralised in Enpp1−/−mice. (F) μCT scanning and (G) histology revealed mineralisation in the cartilage rings of the trachea in Enpp1−/− animals.
(H) Sectioning and alizarin red staining of the ear also revealed mineralisation within this tissue in Enpp1−/−mice. The representative images shown are from 15 (A–C) and 22-week
old (D–H) animals. Scale bars: E = 100 μm, G = 150 μm, H= 50 μm.
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showed that the collagenous sheath surrounding the whisker follicles
in Enpp1−/−mice contained calcium mineral. No other mineralisation
was detected in this tissue and the smaller hair follicles, which are not
surrounded by collagen, were not mineralised (Fig. 1E). μCT analysis
and histology also demonstrated mineralisation within the cartilage
rings of the trachea (Figs. 1F & G) and the ear pinna of Enpp1−/−mice
(Figs. 1D & H).
In all cases, soft tissue mineralisation was evident from 8 weeks and
worsened with age; the representative images shown are from 15
(Figs. 1A–C) and 22-week old (Figs. 1D–H) animals.
Enpp1−/− mice have thinner and less porous cortical bone with a bigger
bone marrow cavity
This study used high resolution μCT to examine in detail how NPP1
deletion affects cortical bone structure. Representative images of the
cortical bone at 8, 15 and 22-weeks are shown in Fig. 2A. No differences
in any of the cortical bone parameters measured were observed in the
8-week animals (Fig. 2). Cortical bone volume was decreased up to
28% in Enpp1−/− mice (Fig. 2B). This was accompanied by 16% and
35% reduction in cortical thickness in 15 and 22-week old Enpp1−/− an-
imals, respectively (Fig. 2C). Enpp1+/+ mice displayed increasing corti-
cal thickness with age (57% higher at 22-weeks compared to 8-weeks);
this age-related increase in cortical thickness did not occur in Enpp1−/−
mice (Fig. 2C). The endosteal diameter, which represents the diameterof the bone marrow cavity, was increased up to 23% in Enpp1−/−mice
(Fig. 2D). The periosteal diameter was unchanged by NPP1 deletion
(Fig. 2E).
Total porosity represents all the spacewithin the cortical bone that is
not filled by bone mineral e.g. blood vessels channels or osteocyte lacu-
nae. We found that total porosity was decreased 30% and 60% in 15 and
22-week old Enpp1−/−mice, respectively (Figs. 2A & F). The total vol-
ume of closed pores, which equates to the spaces totally enclosed by
mineral, was reduced up to 55% in Enpp1−/− animals (Fig. 2G). The
number of closed pores was decreased 40% and 59% at 15 and 22-
weeks, respectively (Fig. 2H). Pore diameter was reduced up to 15% in
Enpp1−/−mice (Fig. 2I).
Differences in the total x-ray attenuation of the μCT scans can indi-
cate whether a tissue is hypermineralised (i.e. the matrix is overly
mineralised). Analysis of the x-ray attenuation within the cortical
bone revealed no differences between the Enpp1+/+ and Enpp1−/−
mice at any age (not shown).
Reduced size of vascular channels and osteocyte lacunae in Enpp1−/−mice
Low power SEM analysis of the femur showed that the number and
size of the vascular channels on the endosteal surface of the cortical
bone was reduced up to 50% and 70%, respectively in Enpp1−/− mice
(Figs. 3A–C & E–F). SEM at higher power was then used to visualise
osteocyte lacunae on cortical bone surfaces (Figs. 3B & D). Quantifica-
tion of SEM images showed that the lacunae diameter was reduced up
Fig. 2. Enpp1−/−micedisplay significant changes in the cortical bone. Humerus bones from8, 15 and 22-week oldmicewere scannedby μCT at a resolution of 0.9 μm.Measurementswere
performed on a region of interest 0.25 mm in length, 0.5 mm below the deltoid tuberosity. (A) Representative images of the cortical bone from Enpp1+/+ and Enpp1−/−mice. The grey
regions represent the bone and the red areas the spaceswithin the bone. No differences in the cortical bonewere observed in 8-week old animals. (B) Cortical bone volumewas decreased
by≤24% in Enpp1−/−mice. (C) Cortical thickness was reduced 16% and 35% in 15 and 22-week old Enpp1−/−mice, respectively. (D) The endosteal diameter was increased up to 23% in
Enpp1−/− animals. (E) The periosteal diameter was unchanged by NPP1 deletion. (F) Total porosity was decreased 30% and 60% in 15 and 22-week old Enpp1−/− mice, respectively.
(G) The total volume of closed pores was reduced up to 55% in Enpp1−/− animals. (H) The number of closed pores was decreased 40% and 59% at 15 and 22-weeks, respectively.
(I) Pore diameter was reduced up to 15% in Enpp1−/−mice. Values are means ± SEM (n= 5–10), *** = p b 0.001, ** = p b 0.01, * = p b 0.05..
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was decreased 35% and 39% in 15 and 22-week old Enpp1−/− animals
(Fig. 3G). It was also noted that in Enpp1+/+ animals there was a reduc-
tion in the size of the osteocyte lacunae as the animals aged (Fig. 3G).
Expression of NPP1 by mouse osteocyte-like cells
Mouse osteocyte-like cells extracted from the longbones of 15-week
old Enpp1−/− and Enpp1+/+mice displayed the characteristic dendritic
processes of osteocytes (Figs. 4A & B). RT-PCR showed that Enpp1+/+
osteocyte-like cells express mRNA for the osteocyte specific gene,
DMP1, and for Enpp1 (Fig. 4C).
Increased sclerostin levels in Enpp1−/−mice
Sclerostin mRNA expression was increased ~9-fold in osteocytes
(Fig. 4D) and ~16-fold in mature, bone forming osteoblasts (Fig. 4E)
derived from Enpp1−/−mice. No differences in the serum concentration
of sclerostin were seen in 8-week old animals. However, sclerostin
levels were increased 75% and 52% in 15 and 22-week old Enpp1−/−
mice, respectively (Fig. 4F). In Enpp1+/+ animals, ageingwas associated
with a 62% reduction in serum sclerostin levels; this decrease was not
seen in Enpp1−/−mice.
Reduced number and ATP release in cultures of Enpp1−/− osteocyte-like
cells
Osteocyte-like cells extracted from the bones of Enpp1−/− and
Enpp1+/+ mice were cultured for 7 days. The number of osteocyte-
like cells was reduced by 48% in Enpp1−/− cultures (Fig. 4G).Constitutive ATP release from Enpp1−/− osteocyte-like cells into the cul-
ture medium was decreased by 80% compared to Enpp1+/+ cells
(Fig. 4H).
Osteoclasts expressed mRNA for NPP1 and other ecto-nucleotidases
RT-PCR analysis was performed on osteoclast precursors (day 3),
early osteoclasts (day 6), mature osteoclasts (day 8) andmature resorb-
ing osteoclasts (day 10) to investigate the expression of ecto-
nucleotides in these cells. We found that osteoclasts express mRNAs
for Enpp1, Enpp3, NTPdase1, NTPdase3 and the transport protein, Ank,
from day 6 onwards; mRNA expression of Enpp2 and NTPdase 2 was
not detected (Fig. 5A). Enpp1mRNA expression increased as osteoclas-
togenesis progressedwith peak levels inmature, resorbing cells. In con-
trast, mRNA levels of Enpp3 and NTPdase 3 were lower in mature
osteoclasts. Expression of Ank andNTPdase 1mRNA remained relatively
constant (Fig. 5A).
Osteoclasts display NPP activity
Total cellularNPP activitywasmeasured in osteoclasts at all stages of
differentiation. We found that osteoclasts exhibited functional NPP ac-
tivity, which decreased as osteoclastogenesis progressed (Fig. 5B)
Enpp1−/− osteoclasts displayed up to a 70% reduction in total NPP activ-
ity (Fig. 5B).
Osteoclast formation and activity is unaffected by NPP1 deletion
Osteoclasts were generated from 8 and 15-week old Enpp1−/− and
Enpp1+/+mice and cultured on dentine discs for 9 days. Representative
Fig. 3. Reduced vascular channels and smaller osteocyte lacunae in Enpp1−/−mice. Representative SEM images of the femoral endosteal surface from Enpp1+/+ and Enpp1−/−mice.
(A) Vascular channels are reduced in size and number in Enpp1−/− animals. Higher magnification images highlight the decreased size of the (B, C) blood vessel channels and
(B, D) osteocyte lacunae in Enpp1−/−mice. Scale bars: A = 0.5 mm, B = 20 μm, C = 12 μm, D = 5 μm. (E, F) The number and size of blood vessel channels on the endosteal surface
of the bone were reduced up to 50% and 70%, respectively, in Enpp1−/−animals. (G, H) Osteocyte lacunae diameter and surface area were reduced ≤25% and ≤39%, respectively, in
Enpp1−/−mice. Quantitative analysis of blood vessel channels and osteocyte lacunae images based on n = 50 measurements per group; *** = p b 0.001, ** = p b 0.01.
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formed from these animals are shown in Fig. 5C. No differences in oste-
oclast formation or resorptive activity were seen in Enpp1−/− osteo-
clasts from 8-week (Fig. 5D) and 15-week old (not shown) animals.
Discussion
The role of NPP1 in tissue mineralisation has been widely studied
using rodentmodels. In particular, the global ablation of Enpp1−/− func-
tion has provided considerable information about the actions of NPP1 in
different tissues (see review by Mackenzie et al. 2012 [18]). Within
bone, the effects of NPP1 on osteoblast differentiation and function
have been well documented [20,27,28], yet information regarding its
role in osteocytes and osteoclasts is limited. This study demonstrated
for the first time that NPP1 is expressed by both cell types. Using
Enpp1−/− mice we identified a key role for NPP1 in maintaining the
size of osteocyte lacunae.
Earlier investigations reported that Enpp1−/−mice exhibit aberrant
mineralisation of the aorta, joints, spine and cartilage [4,19–21]. During
our μCT analysis of thesemice we also observed extensive ectopic calci-
fication in the above tissues.We additionally sawmineralisation in sev-
eral soft tissues where it had not previously been detected. Thewhisker
follicles, ear pinna and trachea all contain type I or type II collagenwhich
could act as a site formineral deposition. Themineralisation of these tis-
sues in knockout mice suggests that, under normal conditions, produc-
tion of PPi from ATP by NPP1 is important in preventing calcification.
The initial studies of Enpp1−/−mice showed that these animals had
reduced bone mineral content (BMC) in the long bones [27].Subsequent, more detailed analysis by Mackenzie et al. [20] showed
that Enpp1−/−mice display reduced trabecular bone volume, thickness
and number as well as decreased cortical thickness and porosity. In
agreement, we also observed age-related decreases in cortical bone
volume, thickness and porosity. Additionally, we found that whilst the
periosteal diameter was unchanged the endosteal diameter was
increased making the cortical bone in Enpp1−/−mice thinner and less
porous with a larger marrow space. Taken together, these studies
show that the reduced BMC of the long bones originally identified by
Anderson et al. [27] involves decreased bone in both the trabecular
and cortical compartments.
Cortical porosity, as measured using μCT, is a measurement of all of
the spaces within the bone including vascular channels, osteocyte lacu-
nae ormicrocracks. The μCT analysis performed byMackenzie et al. [20]
used a resolution of 5 μm, which although adequate for determining
overall changes in cortical bone volume and porosity, was not sufficient
to provide detailed information about the osteocyte lacunae. Here, we
used higher resolution μCT (0.9 μm) and SEM to examine whether the
changes in cortical porosity could reflect alterations in the size of osteo-
cyte lacunae in Enpp1−/−mice. We found that the number, volume and
diameter of the closed pores were reduced in Enpp1−/− animals; this
was accompanied by a decrease in the number of osteocytes isolated
from the long bones. Subsequent analysis of SEM images also showed
a reduction in lacunar diameter and area. The most likely explanation
for the decreased osteocyte lacunar size in Enpp1−/−mice is a localised
increase in the amount of matrix mineralisation, which could have a
negative impact on osteocyte function and survival. Further studies
will be needed to assess the effect of NPP1 deletion on osteocyte
Fig. 4. The effect of NPP1 deletion on osteocyte number, ATP release and serum sclerostin levels. (A, B) Osteocyte-like cells extracted from the long bones of 15-week old mice displayed
dendritic processes characteristic of these cells. (C) RT-PCR showed mRNA expression of DMP-1 and Enpp1 in Enpp1+/+ osteocyte-like cells. qRT-PCR revealed that sclerostin mRNA
expression was increased. (D) ~9-fold increase osteocytes and (E) ~16-fold in mature, bone forming osteoblasts. (F) Sclerostin levels were increased 75% and 52% in 15 and 22-week
old Enpp1−/−mice, respectively. (D) The number of osteocyte-like cells was reduced 48% in Enpp1−/−cultures. (E) Enpp1−/− cells displayed an 80% decrease in constitutive ATP release.
Values are means ± SEM (n = 5–10), *** = p b 0.001, ** = p b 0.01, * = p b 0.05.
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Previously, increased mineralisation of the osteocyte lacunae has been
linked with ageing [42], osteoporosis and osteoarthritis [25].
Cultured MLO-Y4 osteocyte-like cells have been reported to release
ATP constitutively [43,44]. The present work shows that primary
osteocyte-like cells frommouse long bones also release ATP and, more-
over, express mRNA for NPP1. This suggests that osteocytes are capable
of hydrolysing ATP to generate themineralisation inhibitor, PPi, in their
extracellular environment. Earlierwork has shown that extracellular PPi
levels are reduced in the culture medium of Enpp1−/− osteoblasts [19].
Therefore, it is possible that the decreased lacunar size in Enpp1−/−
mice is due to increased mineralisation that is the result, at least in
part, of a lower concentration of ATP-derived PPi.
Despite exhibiting mineralisation of soft tissues and osteocyte lacu-
nae, Enpp1−/− mice display a decreased trabecular and cortical bone
volume [20]. It has been suggested that the reduced bone seen in
Enpp1−/− animals occurs because there is insufficient PPi for TNAP to
generate the Pi needed for normal bone formation [18]. However, the
reduction in the size and number of the vascular channels within thecortical bone of Enpp1−/−mice could provide a further pathophysiolog-
ical mechanism for the decreased bone mass in these animals. A
decreased vascular supply to the bones, perhaps exacerbated by the
aortic calcification previously described in Enpp1−/− mice [18,45],
would result in hypoxia and acidosis, which are well known to increase
osteoclast formation and resorption [36,37], whilst also inhibiting bone
mineralisation [46–48]. In support of this notion, we observed promi-
nent fields of resorption pits on the endosteal surfaces of Enpp1−/−
bones and Enpp1−/− mice have increased levels of potassium ions,
which can be a marker of acidosis, within the blood [20].
Sclerostin, which is secreted by osteocytes, inhibits Wnt signalling
and negatively regulates bone formation [49]. We found that serum
sclerostin levels were higher in Enpp1−/− mice and that sclerostin
mRNA expression was strongly increased in Enpp1−/− osteocyte-like
cells and mature, bone forming osteoblasts. Previous studies have
shown that mechanical loading regulates sclerostin expression, with
increased levels in unloaded bones [50–54]. Enpp1−/−mice display an
unusual walking gait [17,29], muscle damage [20] and mineralisation
of the spine, knees and toes, which combined are likely to affect the
Fig. 5.NPP1 deletion does not affect the formation or resorptive activity of osteoclasts. (A) RT-PCR analysis was performed on osteoclast precursors (day 3), early osteoclasts (day 6), ma-
ture osteoclasts (day 8) andmature resorbing osteoclasts (day 10), Expression of Enpp1, Enpp3, NTPdase1, NTPdase3 and AnkmRNAwas detected from day 6 onwards (day 3 not shown).
Expression of Enpp2 andNTPdase2mRNAswas not detected. RT-PCR positive control= mouse brain. (B) Osteoclasts exhibit functional NPP activity,which decreases as osteoclastogenesis
progresses. Enpp1−/− osteoclasts displayed up to a 70% reduction in total NPP activity. (C) Representative transmitted (top) and reflective (bottom) light microscopy images of Enpp1+/+
and Enpp1−/− osteoclasts cultured on dentine. Scale bar = 50 μm. (D) No differences in osteoclast formation or resorptive activity was seen in Enpp1−/− osteoclasts. Values are
means ± SEM (n = 8–10), *** = p b 0.001, * = p b 0.05.
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Enpp1−/−micemay be due not only to constitutively higher production
by bone cells but also to decreased mechanical loading. These factors
are consistent with the reduced bone mass observed in these ani-
mals. Enpp1−/− mice also display increased expression of FGF23, an
osteocyte-derived phosphaturic hormone that can inhibit bone
mineralisation [20]. Recently it was reported that sclerostin can indi-
rectly regulate FGF23 expression since sclerostin knockout mice dis-
play reduced levels of serum FGF23 [55]. Therefore, the increased
FGF23 levels in Enpp1−/−mice could be a consequence of the higher
sclerostin levels.
This study demonstrated for the first time that osteoclasts express
several ecto-nucleotidases including NPP1. Osteoclasts also exhibit sig-
nificant NPP activity making them capable of contributing to extracellu-
lar PPi levels. A significant portion of this NPP activity was due to NPP1
suggesting that, like osteoblasts, this is the pre-eminent NPP in osteo-
clasts. μCT analysis showed that whilst the endosteal diameter wasincreased in Enpp1−/− mice, the periosteal diameter was unchanged.
This increase in the endosteal/periosteal ratio is indicative of increased
osteoclast activity in the bone. In agreement, Mackenzie and colleagues
saw histological and biochemical evidence of increased in vivo oste-
oclast activity in Enpp1−/−mice [20]. Our current study found no dif-
ferences in osteoclast formation and activity when Enpp1−/−
osteoclastswere generated in vitro frombonemarrowprecursors. How-
ever, the SEM images shown in Fig. 3 do show an apparent increase in
bone resorption on the endosteal surface of the cortical bone from
Enpp1−/− mice. The discrepancy between the in vitro and in vivo data
suggests that any effects of NPP1 deletion on osteoclasts are mediated
by other cells.
In summary, the work presented here shows that NPP1 plays a key
role in regulating soft tissue and skeletal mineralisation. The ectopic
mineralisation observed in several collagen rich soft tissues suggests
that NPP1 expression is more widespread than previously reported.
Our findings also suggest that expression of NPP1by osteocytes may
147M.O.R. Hajjawi et al. / Bone 69 (2014) 139–147be important in preventing the over-mineralisation of their lacunae
(which could potentially compromise osteocyte function or survival).
Finally, since age-related pathological calcification is a common in
humans, the rapidly worsening phenotype of Enpp1−/− mice may, in
some respects, represent a useful model of accelerated ageing.Acknowledgments
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